Pfizer Inc ((PFE)) announced an update on their ongoing clinical study.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Pfizer Inc. is conducting a Phase 3 clinical study titled ‘A PHASE 3, RANDOMIZED, OPEN-LABEL STUDY OF PF-06821497 (MEVROMETOSTAT) IN COMBINATION WITH ENZALUTAMIDE COMPARED WITH ENZALUTAMIDE OR DOCETAXEL IN PARTICIPANTS WITH METASTATIC CASTRATION RESISTANT PROSTATE CANCER PREVIOUSLY TREATED WITH ABIRATERONE ACETATE (MEVPRO-1)’. The study aims to evaluate the safety and efficacy of PF-06821497 combined with enzalutamide compared to enzalutamide or docetaxel in treating metastatic castration-resistant prostate cancer (mCRPC) following abiraterone acetate treatment. The primary goal is to assess radiographic progression-free survival (rPFS).
The study is testing an investigational drug, PF-06821497, administered at 875 mg twice daily, in combination with enzalutamide, a standard prostate cancer treatment taken at 160 mg daily. The purpose is to determine if this combination improves outcomes compared to enzalutamide or docetaxel alone.
This interventional study is designed as a randomized, open-label trial with a parallel assignment. There is no masking, and the primary purpose is treatment-focused, aiming to provide insights into the effectiveness of the new drug combination.
The study began on October 21, 2024, with its primary completion date yet to be determined. The most recent update was submitted on June 27, 2025. These dates are crucial as they indicate the study’s progress and timeline for potential results.
The outcome of this study could significantly impact Pfizer’s stock performance and investor sentiment, especially if the results demonstrate a substantial improvement in treatment efficacy. This development could also influence the competitive landscape in the prostate cancer treatment market, where other companies are also vying for advancements in mCRPC therapies.
The study is currently ongoing, with further details available on the ClinicalTrials portal.